NWBO - Northwest Biotherapeutics, Inc.
| Previous Close | 0.1770 |
| Open | 0.1810 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1769 - 0.2000 |
| 52 Week Range | 0.1400 - 0.4000 |
| Volume | 2,722,151 |
| Avg. Volume | 1,152,296 |
| Market Cap | 78.579M |
| Beta | 2.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3940 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- ACCESSWIRE•2 months ago
Independent Research on Trending Growth Companies: Northwest Biotherapeutics and Sanuwave Health
NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Northwest Biotherapeutics, Inc. (OTCQB: NWBO) and Sanuwave Health ...
- PR Newswire•2 months ago
NW Bio Congratulates Cognate BioServices On Its Management Buyout
BETHESDA, Md., Feb. 20, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, congratulated Cognate BioServices, the contract manufacturer of NWBio's DCVax® products, on the Management Buyout of Cognate supported by global institutional investors, which Cognate announced today. Following this transaction, neither Linda Powers nor any Toucan Capital related entities have any ownership interest in Cognate or any role on Cognate's Board. More information can be found in a Cognate press release at https://www.businesswire.com/news/home/20180220006077/en.
- PR Newswire•4 months ago
NW Bio Announces Regulation D Offering for Accredited Investors
BETHESDA, Md., Dec. 19, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is commencing a general solicitation Regulation D offering to accredited investors. The Offering will remain open for execution of subscription agreements until 5:30 pm EST on Wednesday, December 27, 2017, and the closing is expected to take place on Friday, December 29, 2017.
- PR Newswire•5 months ago
NW Bio Announces Completion of $12 Million Financing
BETHESDA, Md., Dec. 4, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NWBio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has completed a $12 million financing to fund operations. The majority of the financing is being provided by new investors. The financing is in the form of Series A Convertible Preferred Stock and Warrants. The Preferred Stock will be convertible into common stock, but only when common stock is available or after 6 months following issuance. The Warrants will be exercisable for common stock, but only when common stock is available. The shares are registered, but are subject to restrictions under which they may not be conveyed or traded until a shareholder vote takes place, pursuant to which the number of authorized shares is increased. The shares are also subject to a voting agreement, under which the investors have agreed to vote in support of such increase in authorized shares.
- PR Newswire•6 months ago
NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
BETHESDA, Md., Oct. 30, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company's periodic filings. Every claim was dismissed. On April 12, 2017, the lead plaintiffs submitted a letter to the court advising it that they were not going to file an amended complaint, and the deadline for filing an appeal has now expired. This action is over.
- PR Newswire•6 months ago
NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
BETHESDA, Md., Oct. 25, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company's periodic filings. Every claim was dismissed. On April 12, 2017, the lead plaintiffs submitted a letter to the court advising it that they were not going to file an amended complaint, and the deadline for filing an appeal has now expired. This action is over.
- PR Newswire•7 months ago
NW BIO Announces Registered Direct Offering Of $1.75 Million
BETHESDA, Md., Sept. 20, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $1.75 million. In the transaction, the Company will sell approximately 8.75 million shares of common stock at a purchase price of $0.20 per share. Additionally, the investors will receive five year warrants to purchase up to approximately 4.375 million shares of common stock with an exercise price of $0.22 per share.
- Capital Cube•8 months ago
ETFs with exposure to Northwest Biotherapeutics, Inc. : September 6, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Northwest Biotherapeutics, Inc. Here are 5 ETFs with the largest exposure to NWBO-US. Comparing the performance and risk of Northwest Biotherapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- PR Newswire•8 months ago
DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference
DCVax®-L Phase III GBM Trial & DCVax-Direct Phase I/II Updates; Overview Of A Broader Range Of DC Vax Public Data BETHESDA, Md. , Sept. 1, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW ...
- PR Newswire•10 months ago
NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondholders entered into in March. The convertible debt issued in the transaction has a 3-year maturity.
- PR Newswire•11 months ago
Dr. Marnix Bosch To Present Updates About DCVax® Clinical Programs Today
BETHESDA, Md., June 5, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that this afternoon at 3:00 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, MBA, PhD and Chief Technical Officer of NW Bio, will deliver a webcast update on the Company's clinical trial programs. Dr. Bosch's presentation will include updates on the Company's Phase III trial of DCVax-L for newly diagnosed Glioblastoma multiforme (GBM) brain cancer, as well as the Information Arm related to the GBM trial, and the Company's Phase I/II Trial of DCVax-Direct for inoperable solid tumors.
Capital Cube•11 months agoNorthwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
Categories: Yahoo FinanceGet free summary analysis Northwest Biotherapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Northwest Biotherapeutics, Inc. – Celldex Therapeutics, Inc., Argos Therapeutics, Inc., Stemline Therapeutics, Inc., Agenus Inc., Amgen Inc., Progenics Pharmaceuticals, Inc., Merck & Co., Inc. and ImmunoCellular Therapeutics, Ltd. ... Read more (Read more...)